Illinois-based AI drug discovery company SimBioSys has partnered with Mayo Clinic to develop cloud-based clinical software solutions for breast cancer patients. The terms and financial details of the agreement have not been disclosed.
The collaboration will leverage Mayo Clinic's data to create cloud-powered clinically inclined software tools to facilitate decision-making for early-stage breast cancer patients, including personalized surgical planning and treatment. SimBioSys is also developing a cloud-based platform, TumorSight, currently under FDA evaluation, capable of constructing a 3D digital model from standard patient imaging to assist in surgical planning.
Founded in 2016, SimBioSys focuses on developing precision medicine in cancer care using its software platform that simulates the biochemical interactions within a patient’s tumor to identify the best treatment for the patient. The platform offers metabolic modeling, spatial characterization, drug delivery modeling, and novel biomarkers.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.